Abstract 779PD
Background
Prior data indicate that large RPLN significantly increases the risk of VTE in pts with mGCT receiving first line platinum based chemotherapy (chemo). The aim of this multinational G3 study was to validate large RPLN as a risk factor for VTE and evaluate other predictive factors.
Methods
Data were collected retrospectively from sequential pts with mGCT receiving first line chemo from 2000-2014 at 22 centres. Pre-defined variables of interest included IGCCCG risk classification, axial long axis diameter of largest RPLN, Khorana score (validated predictor for chemo associated VTE), LDH, prior VTE and presence of venous access device (VAD). VTE occurring at baseline, during chemo and within 90 days of completion were analysed. Pts receiving thromboprophylaxis (TP) were excluded. Predictive accuracy was assessed using logistic regression and discriminatory accuracy explored using area under the receiver operating curve (AUC).
Results
Data from 1135 pts were collected. Median age was 31 (range 10-74). Testicular primary (92%), non-seminoma histology (72%) and BEP chemo (82%) were most common. IGCCCG risk distribution was 64% good, 20% intermediate and 16% poor. VTE occurred in 150 pts (13%). RPLN >3.5cm demonstrated highest discriminatory accuracy (AUC 0.68, p 3.5cm was associated with significantly higher risk of VTE (22% versus 8%, OR 3.4, p
Conclusions
This study confirms large RPLN (>3.5cm) as an independent risk factor for VTE in mGCT pts receiving first line chemo. Prospective trials examining TP in this high risk population are warranted.
Clinical trial identification
Not applicable
Legal entity responsible for the study
N/A
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
Presenter: Jean-Charles Soria
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Quality of life (QoL) and neurotoxicity in germ-cell cancer survivors (GCCS)
Presenter: Jakob Lauritsen
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma
Presenter: James Larkin
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
Presenter: Arjun Balar
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Invited discussant abstracts 781PD and 782PD
Presenter: Aristotelis Bamias
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast
Invited discussant abstracts 777PD, 778PD, 779PD and 780PD
Presenter: Christian Kollmannsberger
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast
Invited discussant abstracts 773PD, 774PD, 775PD and 776PD
Presenter: Manuela Schmidinger
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Daniel Petrylak
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Joaquim Bellmunt
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Immunotherapy will be “THE OPTION” in first and second line urothelial tumors
Presenter: Laurence Albiges
Session: Genitourinary tumours, non-prostate
Resources:
Presentation
Webcast